Choroidal Neovascularization Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Additional Information

GlobalData, the industry analysis specialist, has released its new report, “Choroidal Neovascularization Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global choroidal neovascularization (CNV) market. The report identifies the key trends shaping and driving the global CNV market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CNV sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Choroidal Neovascularization Therapeutics Market is Forecast to Show high Growth until 2017

GlobalData forecasts the global Choroidal Neovascularization (CNV) therapeutics market to grow at 6.8% annually for the next seven years, to reach $4.19 billion by 2017. It was valued at $2.6 billion in 2010. This significant growth is primarily attributed to an increase in treatment rates and a high annual cost of therapy for the approved market drugs. The market has experienced tremendous growth due to the introduction of anti-VEGF (Vascular Endothelial Growth Factor) drugs for the treatment of CNV.

Choroidal Neovascularization Therapeutics Market, Global, Revenue and Forecasts ($m), 2005-2017

Source: GlobalData, Age-Related Macular Degeneration: A Guide for the Primary Care Physician, Journal of the national medical association, 2009; John Gever, Bevacizumab Tops Anti-VEGF Choice in AMD, (Age related macular degeneration), 2010

Current Treatment Options are Successful in Meeting Market Demand

GlobalData’s analysis indicates that the current competition in the CNV therapeutics market is strong and the available treatment options have been successful in meeting the market need. The current marketed products are successful in treating the underlying cause of the disease. The extent of unmet need in the CNV therapeutics market is considered to be low. The current market drugs include Lucentis (ranibizumab), approved for CNV associated with wet age related macular degeneration (AMD), Visudyne (verteporfin), approved for CNV associated with wet AMD, presumed ocular histoplasmosis and pathologic myopia, and Macugen (pegaptanib), approved for CNV associated with wet AMD. Apart from these there is Avastin (bevacizumab), which is not approved for CNV (off-label) and is in Phase III of clinical development, has gradually captured a major share of the market.

Strong Pipeline Candidates are Expected to Intensify Future Competition

GlobalData found that there are 38 products in different stages of development. In Phase III trials of clinical development, VEGF-trap eye is being tried for CNV associated with AMD, Lucentis for CNV associated with pathologic myopia and Avastin for both CNV associated with pathological myopia and AMD. VEGF-trap eye can reduce the dose frequency and has potential in the CNV therapeutics market. These products are expected to meet some of the unmet needs in the market and will provide physicians with a wider choice in treating CNV. Apart from this, Avastin which is currently used as an off-label drug will intensify the market competition once approved. In summary, the global CNV therapeutics market is heading towards a highly competitive landscape.

Current Treatment Options Leave a Low Level of Unmet Need

The current CNV therapeutics market is strong and a significant share is held by Lucentis and Avastin (off-label). Other approved therapies include Macugen and Photo Dynamic Therapy (PDT), and Visudyne also has a low market share. The current treatments have a high level of efficacy and safety and have been successful in treating CNV effectively. This leads to high patient and physician satisfaction and results in a low level of unmet need in the CNV therapeutics market.